Regulon: R-3397
Regulons are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio, its Regulator, the Transcriptional Program that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
| Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
|---|---|---|---|---|---|
| 8 | 2.13646 | 1 | 4 | Pr-40 |           |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
| Entrez ID | EnsEMBL ID | Preferred Name | Uniprot ID |
|---|---|---|---|
| 28951 | ENSG00000071575 | TRIB2 | Q92519 |
| 56062 | ENSG00000102271 | KLHL4 | Q9C0H6 |
| 5786 | ENSG00000132670 | PTPRA | P18433 |
| 238 | ENSG00000171094 | ALK | Q9UM73 |
| 339166 | ENSG00000179314 | WSCD1 | Q658N2 |
| 51268 | ENSG00000179761 | PIPOX | Q9P0Z9 |
| 9628 | ENSG00000182732 | RGS6 | P49758 |
| 6263 | ENSG00000198838 | RYR3 | Q15413 |
Regulon Drugs
| Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
|---|---|---|---|---|---|---|
| ASP-3026 | ALK | Small molecule | INHIBITOR | ALK tyrosine kinase receptor inhibitor | 1 | 0 |
| ALECTINIB | ALK | Small molecule | INHIBITOR | EML4-ALK | 4 | 1 |
| BRIGATINIB | ALK | Small molecule | INHIBITOR | ALK tyrosine kinase receptor inhibitor | 4 | 0 |
| LORLATINIB | ALK | Small molecule | INHIBITOR | EML4-ALK inhibitor | 4 | 0 |
| ALECTINIB HYDROCHLORIDE | ALK | Small molecule | INHIBITOR | EML4-ALK | 4 | 0 |
| ENTRECTINIB | ROS1 | Small molecule | INHIBITOR | Neurotrophic tyrosine kinase receptor inhibitor | 4 | 0 |
| DANTROLENE | RYR3 | Small molecule | ANTAGONIST | Ryanodine receptor 1 antagonist | 4 | 0 |
| CRIZOTINIB | ALK | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 1 |
| PLB1003 | ALK | Unknown | INHIBITOR | ALK tyrosine kinase receptor inhibitor | 1 | 0 |
| ENSARTINIB | ALK | Small molecule | INHIBITOR | ALK tyrosine kinase receptor inhibitor | 3 | 0 |
| DANTROLENE SODIUM | RYR3 | Small molecule | ANTAGONIST | Ryanodine receptor 1 antagonist | 4 | 0 |
| CEP-37440 | ALK | Small molecule | INHIBITOR | Focal adhesion kinase 1 inhibitor | 1 | 0 |
| CONTELTINIB | PTK2 | Small molecule | INHIBITOR | Protein tyrosine kinase 2 beta inhibitor | 1 | 0 |
| CERITINIB | ALK | Small molecule | INHIBITOR | EML4-ALK | 4 | 2 |
Causal Flows
Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation may causally activates or deactivates a downstream regulator which then might up- or down-regulates a regulon that contains genes with similar expression profiles and binding sites.